Drug intelligence / Profile preview

Zhuyang Bufei Chubi granule

Development stage: Preclinical
Lead developer: Hospital Affiliated to Changchun University of Traditional Chinese Medicine
Administration: Oral

Overview

Zhuyang Bufei Chubi granule is a traditional Chinese medicine formulation that has been evaluated in clinical studies for its potential therapeutic effects. It has been investigated for the treatment of pulmonary fibrosis, particularly in the context of convalescence from novel coronavirus pneumonia (COVID-19). Research suggests its mechanism may involve inhibiting pulmonary fibrosis by regulating miR-199-mediated TGF-β receptor degradation. In traditional Chinese medicine terms, its name suggests functions such as tonifying Yang, supplementing the lung (Bufei), and removing obstruction (Chubi).

Other names: Zhuyang Bufei Chubi助阳补肺除痹颗粒

Targets

TGFBR (TGF-beta receptor)

Beyond the preview

Go deeper on Zhuyang Bufei Chubi granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhuyang Bufei Chubi granule.

Explore the full profile